Many intracellular pathogens infect a broad range of host tissues, but the importance of T cells for immunity in these sites is unclear because most of our understanding of antimicrobial T cell responses comes from analyses of lymphoid tissue. Here, we show that in response to viral or bacterial infection, antigen-specific CD8 T cells migrated to nonlymphoid tissues and were present as long-lived memory cells. Strikingly, CD8 memory T cells isolated from nonlymphoid tissues exhibited effector levels of lytic activity directly ex vivo, in contrast to their splenic counterparts. These results point to the existence of a population of extralymphoid effector memory T cells poised for immediate response to infection.
REFERENCES AND NOTES
Kagi D., Ledermann B., Burki K., Zinkernagel R. M., Hengartner H., Annu. Rev. Immunol. 14, 207 (1996).
Harty J. T., Tvinnereim A. R., White D. W., Annu. Rev. Immunol. 18, 275 (2000).
Dobber R., Hertogh-Huijbregts A., Rozing J., Bottomly K., Nagelkerken L., Dev. Immunol. 2, 141 (1992).
Zimmermann C., Brduscha-Riem K., Blaser C., Zinkernagel R. M., Pircher H., J. Exp. Med. 183, 1367 (1996).
Butz E. A., Bevan M. J., Immunity 8, 167 (1998).
K. J. Flynn et al., Immunity8, 683 (1998).
K. Murali-Krishna et al., Immunity8, 177 (1998).
Busch D. H., Pilip I. M., Vijh S., Pamer E. G., Immunity 8, 353 (1998).
Kim S. K., Schluns K. S., Lefrançois L., J. Immunol. 163, 4125 (1999).
Bruno L., Kirberg J., von Boehmer H., Immunity 2, 37 (1995).
Busch D. H., Pilip I., Pamer E. G., J. Exp. Med. 188, 61 (1998).
Butcher E. C., Picker L. J., Science 272, 60 (1996).
Dutton R. W., Bradley L. M., Swain S. L., Annu. Rev. Immunol. 16, 201 (1998).
von Andrian U. H., Mackay C. R., N. Engl. J. Med. 343, 1020 (2000).
Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A., Nature 401, 708 (1999).
R. R. Wagner, The Rhabdoviruses (Plenum, New York, 1987).
T. M. Kundig et al., Immunol. Rev.150, 63 (1996).
T. M. Kundig et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9716 (1996).
Van Bleek G. M., Nathenson S. G., Nature 348, 213 (1990).
Altman J. D., et al., Science 274, 94 (1996).
For production of MHC class I tetramers, bacteria-produced H-2Kb containing the BirA-dependent biotinylation substrate sequence was folded in the presence of human β2-microglobulin and the VSV-N peptide. Biotinylation was performed with biotin-protein ligase (Avidity, Denver, CO). Tetramers were then produced from biotinylated, high-performance liquid chromatography–purified monomers by addition of streptavidin-allophycocyanin (APC; Molecular Probes, Eugene, OR).
Cho B. K., Wang C., Sugawa S., Eisen H. N., Chen J., Proc. Natl. Acad. Sci. U.S.A. 96, 2976 (1999).
C. Pope et al., J. Immunol.166, 3402 (2001).
Puddington L., Bevan M. J., Rose J. K., Lefrançois L., J. Virol. 60, 708 (1986).
J. W. Yewdell et al., J. Exp. Med.163, 1529 (1986).
Selin L. K., Welsh R. M., J. Immunol. 158, 5366 (1997).
D. Masopust, L. Lefrançois, unpublished data.
Masopust D., Jiang J., Shen H., Lefrançois L., J. Immunol. 166, 2348 (2001).
Slifka M. K., Whitmire J. K., Ahmed R., Blood 90, 2103 (1997).
Belz G. T., Altman J. D., Doherty P. C., Proc. Natl. Acad. Sci. U.S.A. 95, 13812 (1998).
E. J. Usherwood et al., J. Virol. 73, 7278 (1999).
K. Murali-Krishna et al., Science286, 1377 (1999).
Before tissue removal, mice were perfused with phosphate-buffered saline and heparin (75 U/ml). IEL and LP cells were isolated as described (9). Lung tissue was minced and incubated with stirring at 37°C for 30 min in Hanks' balanced salt solution (HBSS) with 1.3 mM EDTA, followed by treatment at 37°C for 1 hour with collagenase (150 U/ml; 17018-037, Gibco-BRL) in RPMI with 5% fetal calf serum. The resulting suspension was pelleted by centrifugation, resuspended in 44% Percoll (Pharmacia) layered on 67.5% Percoll, and centrifuged at 600g. Cells at the gradient interface were harvested and washed extensively before use. Liver tissue was mashed through a 70-μm strainer in HBSS with 2% fetal calf serum and 10 mM Hepes. The resulting suspension was centrifuged and the pellet resuspended in a solution of 35% Percoll and heparin (200 U/ml) and centrifuged at 600g. Cells in the resulting pellet were treated with tris–ammonium chloride to remove red blood cells and then washed extensively before use.
We thank J. Altman for modified H-2Kb cDNA and E. Pamer for β2-microglobulin constructs. Supported by U.S. Public Health Service (USPHS) grants DK45260 and AI41576, by USPHS training grant T32-AI07080 (D.M. and V.V.), and by a collaborative grant from the Edward Jenner Institute for Vaccine Research and a C. J. Martin Fellowship (007151) (A.L.M.).
Volume 291 | Issue 5512
23 March 2001
23 March 2001
You are viewing the most recent version of this article.
Received: 8 January 2001
Accepted: 16 February 2001
Published in print: 23 March 2001
Request permissions for this article.
Select the format you want to export the citation of this publication.
Download this article as a PDF fileDownload PDF